全文获取类型
收费全文 | 28263篇 |
免费 | 2348篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 346篇 |
儿科学 | 1010篇 |
妇产科学 | 672篇 |
基础医学 | 3415篇 |
口腔科学 | 563篇 |
临床医学 | 3641篇 |
内科学 | 5199篇 |
皮肤病学 | 430篇 |
神经病学 | 2769篇 |
特种医学 | 998篇 |
外科学 | 3574篇 |
综合类 | 647篇 |
一般理论 | 46篇 |
预防医学 | 3155篇 |
眼科学 | 502篇 |
药学 | 2117篇 |
2篇 | |
中国医学 | 33篇 |
肿瘤学 | 1520篇 |
出版年
2021年 | 396篇 |
2020年 | 233篇 |
2019年 | 346篇 |
2018年 | 415篇 |
2017年 | 297篇 |
2016年 | 357篇 |
2015年 | 403篇 |
2014年 | 611篇 |
2013年 | 921篇 |
2012年 | 1169篇 |
2011年 | 1321篇 |
2010年 | 741篇 |
2009年 | 544篇 |
2008年 | 1155篇 |
2007年 | 1272篇 |
2006年 | 1263篇 |
2005年 | 1186篇 |
2004年 | 1180篇 |
2003年 | 1022篇 |
2002年 | 964篇 |
2001年 | 961篇 |
2000年 | 974篇 |
1999年 | 770篇 |
1998年 | 277篇 |
1997年 | 263篇 |
1996年 | 226篇 |
1995年 | 232篇 |
1992年 | 685篇 |
1991年 | 703篇 |
1990年 | 654篇 |
1989年 | 600篇 |
1988年 | 592篇 |
1987年 | 549篇 |
1986年 | 558篇 |
1985年 | 538篇 |
1984年 | 423篇 |
1983年 | 416篇 |
1982年 | 267篇 |
1981年 | 250篇 |
1980年 | 226篇 |
1979年 | 423篇 |
1978年 | 308篇 |
1977年 | 265篇 |
1976年 | 239篇 |
1975年 | 229篇 |
1974年 | 299篇 |
1973年 | 261篇 |
1972年 | 233篇 |
1971年 | 226篇 |
1970年 | 207篇 |
排序方式: 共有10000条查询结果,搜索用时 10 毫秒
61.
Rats were implanted with bilateral cannulas in an area just medial to the ventral nucleus of the lateral lemniscus, an obligatory relay along the acoustic startle pathway. Bilateral infusions of excitatory amino acid transmitter antagonists into this region (10, 25 or 50 nmol per side) produced a rapid, dose-dependent depression of acoustic startle. gamma-D-Glutamylglycine, gamma-D-glutamylaminomethyl sulfonate and 2-amino-5-phosphonovalerate were equally effective in depressing the startle response over this dose range. These results indicate that excitatory amino acid transmitters play an important role in the expression of acoustic startle at this part of the startle pathway. 相似文献
62.
Stromal keratitis and iritis developed in the left eye of a healthy 45-year-old man with no history of ocular disease, trauma, or contact lens wear. The clinical course over a 2-year period was characterized by progressive central disciform keratitis, recurrent anterior stromal patchy infiltration, and iritis which was partially controlled with topical corticosteroids and broad-spectrum antibiotics. Results of bacterial, viral, fungal, and chlamydial cultures were negative. Results of histopathologic examination of a corneal biopsy specimen and, later, a penetrating keratoplasty specimen showed many extracellular and intracellular spores in degenerating keratocytes. By electron microscopy there were encapsulated oval structures measuring approximately 3.5 to 4 microns in length x 1.5 microns in width. Mature spores had well-developed cell walls that contained two abutted nuclei (diplokaryon) and a redundant polar tubule with six coils. These structures are characteristic of a protozoa in the genus Nosema. 相似文献
63.
V Raptopoulos A Davidoff A Karellas M A Davis B L Coolbaugh E H Smith 《AJR. American journal of roentgenology》1988,150(6):1303-1306
Visualization of the head of the pancreas by CT was prospectively evaluated in two groups of 100 patients who did not have pancreatic disease. Patients were given either a fat-density oral contrast material (12.5% corn-oil emulsion and metoclopramide) or a conventional high-density oral contrast material (barium suspension or iodinated solution). There was no statistically significant difference in the subjects' tolerance to the two regimens. There was, however, a significant improvement in ability to distinguish the head of the pancreas from the duodenal C-loop when the fat-density contrast material was given. When pancreaticoduodenal discrimination was graded, patients given corn-oil emulsion and metoclopramide received an average score of 0.94, whereas those given the high-density agent received an average score of 0.74, with 1.00 being the highest possible score (p less than .005). These data suggest that for routine CT evaluation of the head of the pancreas, a combination of corn-oil emulsion and metoclopramide may be superior to the conventional high-density oral contrast agents given without metoclopramide. 相似文献
64.
Numerous investigators have reported the safety, cost effectiveness, and low morbidity and mortality of percutaneous endoscopic gastrostomy (PEG) but not studies compare the results of gastroenterologists and surgeons performing PEG. In a retrospective review of PEG performed at our institution, morbidity and mortality were compared between these two groups. The procedure was performed by either the surgical service (n = 49) or gastroenterology service (n = 51). One hundred PEGs were successfully placed in 92 patients. Three placement failures occurred in the gastroenterology group. Major complications were defined as conditions requiring operative intervention or resulting in death. Minor complications, using a defined list (13 different complications), were those not serious or life-threatening, which were managed medically or resolved without treatment. Twenty-nine minor (17 patients) complications and 3 major (3 patients) complications occurred in the gastroenterology group. Thirteen minor (11 patients) complications and 4 major (4 patients) complications occurred in the surgery group. Overall 30-day mortality was 14 per cent (13 patients), two of which were probably procedure-related in the gastroenterology group. In both groups, there was no difference in the numbers of patients who had complications (P greater than 0.05). The complication rate (numbers of complications/number of patients) doubled in the gastroenterology group compared with the surgery group for minor (P less than 0.04) and total complications (minor and major--P less than 0.06). Since PEG is a procedure frequently performed by gastroenterologists, it is imperative that surgeons, particularly those not performing endoscopy, be aware of the potential morbidity associated with PEG. 相似文献
65.
J E Comaty P G Janicak J Rajaratnam R P Sharma D Baker J M Davis 《Psychopharmacology bulletin》1990,26(2):267-270
The authors designed a three-phase prospective trial in which only those patients who developed an acute, neuroleptic-induced extrapyramidal side effect (EPSE) received benztropine (BZ) at 2 mg i.m. and then 1 mg p.o. b.i.d. for 2 days after their symptoms were rated for severity and type (Preparatory Phase 1). They were then randomly assigned under double-blind conditions to continue BZ or be switched to placebo for 8 days (Experimental Phase 2). Finally in Phase 3 (Followup), all patients continued on placebo in a single-blind design until Day 30. If the patient re-experienced an acute EPSE that was of sufficient severity to require immediate BZ administration, he or she was rated, treated, and then dropped from the study. EPSE scores and dropout rates did not differ in Phase 2 between the placebo- and BZ-treated groups. Implications for the continuation, cessation, or intermittent use of antiparkinsonian (AP) drugs are discussed. 相似文献
66.
Metaplastic cystitis complicated with Von Brunn nests, cystitis cystica, and intestinal type of glandular metaplasia 总被引:4,自引:0,他引:4
It is well documented that under certain stimuli the bladder epithelium can undergo metaplasia. The origin of glandular epithelium, which may be found in the bladder, is somewhat controversial. Endoscopic and histopathologic features of an eighty-one-year-old white man with proliferative metaplastic cystitis are presented. This case demonstrates that glandular differentiation was due to progressive cystitis rather than congenital intestinal rest. 相似文献
67.
68.
Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. 总被引:2,自引:0,他引:2
C Anasetti P J Martin R Storb F R Appelbaum P G Beatty J Davis K Doney H F Hill P Stewart K M Sullivan 《Transplantation》1992,54(5):844-851
Treatment with the monoclonal antibody OKT3 specific for the CD3 complex associated with the T cell antigen receptor can reverse acute rejection of human renal allografts. However, efficacy of anti-CD3 antibodies for treatment of patients with acute graft-versus-host disease after marrow transplantation has not been established. The dose-limiting side effects resulting from T cell activation induced by some anti-CD3 antibodies in vivo have discouraged their use for this application. We now report a phase I-II study of GVHD treatment with the anti-CD3 antibody BC3, a monoclonal murine IgG2b that, unlike OKT3, does not activate T cells. Fourteen patients were treated with BC3 after progression of acute GVHD despite treatment with cyclosporine and corticosteroids, and three patients received BC3 as primary treatment for GVHD. BC3 was administered at a dose of 0.1 or 0.2 mg/kg/day for seven or eight days. Five patients achieved complete resolution of GVHD, eight patients had partial improvement, two patients had no change, and two patients had progression of GVHD on therapy. Responses were sustained in 8 of 13 patients. Mild chills, fever, hypertension, and chest discomfort occurred in various combinations following 6 of 17 (35%) initial infusions of BC3 and following 4 of 99 (4%) subsequent infusions. In each instance it was possible to continue BC3 therapy without adjusting the dose or treatment schedule. In each patient treated, the absolute count of peripheral blood lymphocytes decreased transiently but returned to baseline within 22 hr after the first infusion. Circulating T cells had surface CD3 molecules saturated by the infused antibody in all but one patient. Four patients survived longer than one year after treatment with antibody BC3, and 13 patients died of infection or organ failure. Administration of the nonmitogenic anti-CD3 antibody BC3 was associated with improvement in the clinical manifestations of GVHD with minimal acute toxicity. Efficacy of antibody treatment did not depend on depletion of circulating T cells. Therefore, antibody BC3 may be achieving therapeutic immunosuppression by modulating T cell function. Controlled studies in patients treated earlier in the course of GVHD should determine whether antibody BC3 can improve survival. 相似文献
69.
70.
Why should depression screening be conducted in chronically ill populations? Depression is a disabling illness and is very common among patients who have chronic illnesses. Despite its high prevalence in this patient population, depression often goes unrecognized. Having a plan for a population-based screening program for depression can not only identify patients who are at risk of depression, but can also help to foster early treatment and enhanced care for these patients. This article provides an overview of commonly-used depression screening tools and presents an example of how this might be carried out in a healthcare organization. 相似文献